CONCLUSIONS	Although higher rates of adverse events are seen in the oldest subgroup ( age > or = 75 years ) treated with enoxaparin , statistical comparisons confirm similar efficacy and safety of enoxaparin and UFH across age subgroups as was demonstrated overall in SYNERGY .\